Clinical Trial Update: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus plus exemestane in Chinese postmenopausal women with ER-positive locally advanced, recurrent, or metastatic breast cancer af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-01-23